Investment
Features
FeesSafety
Academy
More
Pluang+

First Trust Nasdaq Semiconductor ETF (FTXL) returns 119.6% in one year, outperforming peers but rated Hold due to high valuation.

Analyst Insights
18 Sep 2026
Seeking Alpha
View Source
Neutral
First Trust Nasdaq Semiconductor ETF (FTXL) returns 119.6% in one year, outperforming peers but rated Hold due to high valuation.

The First Trust Nasdaq Semiconductor ETF (FTXL) delivered a strong one-year return of 119.6%, outperforming major semiconductor ETFs like SOXX and SMH by over 18%. This outperformance is attributed to FTXL's unique factor-driven, cash-flow-weighted approach and a portfolio less concentrated in Nvidia. However, the sustainability of this performance is uncertain after the September rebalance due to potential portfolio changes. The ETF is rated Hold because of its high valuation (P/E around 35), a relatively high fee of 0.60%, and the unpredictability of future factor leadership. The expected total return over the next 6–12 months is moderate, around 5–10%, driven mainly by profit growth rather than multiple expansion.

The First Trust Nasdaq Semiconductor ETF (FTXL) is noted for its strong one-year return of 119.6%. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 18, 2026 18:51 WIB: out of 150 priced Technology-sector US stocks tradable on Pluang, 71 rose and 71 fell today. Notable movers include CIFR at USD 17.18 with a 1-day change of +1.42%, FIVN at USD 34.02 with -1.39%, and SONY at USD 23.51 with -1.34%.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
59 minutes ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App